Abstract Number: 0256 • ACR Convergence 2022
Patients with ACPA-positive and ACPA-negative Rheumatoid Arthritis Show Different Circulating Auto-antibody Repertoires
Background/Purpose: RA is commonly diagnosed through a serological test for the presence of ACPA, and RA patients who test positive are collectively known as 'ACPA-positive…Abstract Number: 0272 • ACR Convergence 2022
Long-Term Efficacy of Baricitinib in Patients with Rheumatoid Arthritis with Inadequate Response to Bdmards: Results from RA-BEYOND up to 6.9-Years of Treatment
Background/Purpose: Baricitinib (BARI), an oral selective Janus kinase 1/2 inhibitor, is approved for treatment of adults with moderately-to-severely active rheumatoid arthritis (RA). BARI demonstrated efficacy…Abstract Number: 0290 • ACR Convergence 2022
Evaluation of Treatment Discontinuation Due to Adverse Events, and the Effect of Cardiovascular Risk Factors or Type of JAK-inhibitors: An International Collaboration of Registries of Rheumatoid Arthritis Patients (the ‘JAK-pot‘ Study)
Background/Purpose: The "ORAL Surveillance" study1 suggests an increased risk of serious adverse events (AEs) with tofacitinib, a JAK-inhibitor (JAKi), compared to TNF-inhibitors (TNFi). Currently, there…Abstract Number: 0307 • ACR Convergence 2022
Reduction in Structural Damage Progression and Improvement in Clinical Response with Abatacept Treatment in Patients with ACPA+, Early RA: Results from a Post Hoc Analysis of the AVERT-2 Study by Baseline Erosion Scores
Background/Purpose: Presence of structural damage is an important risk factor for further damage progression over time in RA. Inhibition of damage progression is a key…Abstract Number: 0530 • ACR Convergence 2022
Abatacept Significantly Reduces Subclinical Inflammation During Treatment (6 Months), This Persists After Discontinuation (12 Months), Resulting in a Delay in the Clinical Development of RA in Patients at Risk of RA (The ARIAA Study)
Background/Purpose: Development of the clinical phase of rheumatoid arthritis (RA) is preceded by an autoimmune phase, characterized by the presence of anti-citrullinated protein antibodies (ACPA),…Abstract Number: 0585 • ACR Convergence 2022
Baricitinib Inhibits Proinflammatoly Cytokine Production, Proliferation and Cell Migration in Human Lung Fibroblasts
Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by inflammation and joint destruction. Baricitinib is a selective small molecule inhibitor of JAK 1…Abstract Number: 0604 • ACR Convergence 2022
Altered Metabolic State in Myeloid Precursors and Mature Cells Within Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease characterised by synovial inflammation and joint destruction. Prior research has revealed perturbation in the myeloid compartment of…Abstract Number: 0622 • ACR Convergence 2022
Commensal Reactive T-cells Display Diverse Phenotype in Rheumatoid Arthritis Patients
Background/Purpose: Past studies have shown a critical link between alteration in human commensal microbiota and development of Rheumatoid Arthritis (RA), however how CD4+ T-cell responses…Abstract Number: 0750 • ACR Convergence 2022
Quality Improvement Project to Increase the Rate of Vaccination with Pneumococcal Vaccines (PCV13 prime-PPSV23 Boost Strategy) Among Adult Patients with Autoimmune Inflammatory Rheumatic Diseases (AIIRD) Within Nationwide Health Organization
Background/Purpose: Patients with autoimmune inflammatory rheumatic diseases (AIIRD) are susceptible for pneumococcal disease. Two vaccines against S. pneumoniae are currently recommended for use: a 23-valent…Abstract Number: 0802 • ACR Convergence 2022
Is There Any Relationship Between Helicobacter Pylori and Rheumatoid Arthritis?
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by joint damage. Recently, several studies suggest that gut microbiota could promote RA progression. Helicobacter…Abstract Number: 0894 • ACR Convergence 2022
DAS28-gGT for the Prediction of Major Cardiovascular Events in Rheumatoid Arthritis: Results from the ESPOIR Cohort
Background/Purpose: Patients with rheumatoid arthritis (RA) experience premature mortality that is largely due to cardiovascular disease (CVD). Ample evidence suggests that elevated γGT activity is…Abstract Number: 0910 • ACR Convergence 2022
Rheumatoid Arthritis Associated Interstitial Lung Disease: The Role of Non-Criteria Autoantibodies
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic joint inflammation. RA-associated interstitial lung disease (ILD) is the most frequent and severe extra-articular…Abstract Number: 0926 • ACR Convergence 2022
Methotrexate Polyglutamates Exposure – Response Modelling in a Large Cohort of Rheumatoid Arthritis Patients Starting Methotrexate
Background/Purpose: Optimal dosing of low-dose methotrexate (MTX) is a challenge in rheumatoid arthritis (RA) because of substantial interpatient variation of response and because no stable…Abstract Number: 1039 • ACR Convergence 2022
Differential Retention of Adalimumab and Etanercept Biosimilars Compared to Originator Treatments: Results of a Retrospective French Multicentre Study
Background/Purpose: Studies have demonstrated equivalence in term of efficacy and safety of biosimilars (bsDMARDs) compared to the originals treatments (boDMARDs) and in switching situation. Less…Abstract Number: 1207 • ACR Convergence 2022
Risk Factors for Major Cardiovascular Events (MACE) in Inflammatory Arthritis: A Time-dependent Analysis on the Inflammatory Burden, Use of DMARDs, NSAIDs, and Steroid
Background/Purpose: Inflammatory arthritis (IA) including rheumatoid arthritis (RA) and psoriatic arthritis (PsA) is associated with accelerated atherosclerosis due to systematic inflammation. To elucidate whether inflammatory…
- « Previous Page
- 1
- …
- 85
- 86
- 87
- 88
- 89
- …
- 188
- Next Page »